Energy and the Alzheimer brain

Aagesen, 1984, Advanced grandmaternal age on the mother’s side—a risk of giving rise to trisomy 21, Ann. Hum. Genet., 48, 297, 10.1111/j.1469-1809.1984.tb00843.x Abramov, 2009, Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses, Nat. Neurosci., 12, 1567, 10.1038/nn.2433 Aliyev, 2005, Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer’s disease, J. Neurol. Sci., 229–230, 285, 10.1016/j.jns.2004.11.040 Appelberg, 2009, The effects of a ketogenic diet on behavioral outcome after controlled cortical impact injury in the juvenile and adult rat, J. Neurotrauma, 26, 497, 10.1089/neu.2008.0664 Arbuzova, 2001, Familial Down syndrome: evidence supporting cytoplasmic inheritance, Clin. Genet., 60, 456, 10.1034/j.1399-0004.2001.600609.x Arbuzova, 2002, Mitochondrial dysfunction and Down’s syndrome, Bioessays, 24, 681, 10.1002/bies.10138 Arbuzova, 1998, Why is it necessary to study the role of mitochondrial genome in trisomy 21 pathogenesis, Down Syndr. Res. Pract., 5, 26, 10.3104/reports.88 Arendt, 2015, Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer’s disease pathology, J. Neural Transm. (Vienna), 122, 531, 10.1007/s00702-014-1342-8 Ashby, 2013, Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer’s disease, Expert Opin. Investig. Drugs, 22, 1229, 10.1517/13543784.2013.812631 Attems, 2013, Amyloid and tau: neither chicken nor egg but two partners in crime!, Acta Neuropathol., 126, 619, 10.1007/s00401-013-1167-9 Attems, 2014, The overlap between vascular disease and Alzheimer’s disease—lessons from pathology, BMC Med., 12, 206, 10.1186/s12916-014-0206-2 Attems, 2012, The relationship between subcortical tau pathology and Alzheimer’s disease, Biochem. Soc. Trans., 40, 711, 10.1042/BST20120034 Avila, 2010, Alzheimer disease: caspases first, Nat. Rev. Neurol., 6, 587, 10.1038/nrneurol.2010.157 Bach, 2009, New insights into {gamma}-aminobutyric acid catabolism: evidence for {gamma}-hydroxybutyric acid and polyhydroxybutyrate synthesis in Saccharomyces cerevisiae, Appl. Environ. Microbiol., 75, 4231, 10.1128/AEM.00051-09 Bailey, 2004, The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease, Neurol. Res., 26, 573, 10.1179/016164104225016272 Baloyannis, 2012, The vascular factor in Alzheimer’s disease: a study in Golgi technique and electron microscopy, J. Neurol. Sci., 322, 117, 10.1016/j.jns.2012.07.010 Baloyannis, 2006, Mitochondrial alterations in Alzheimer’s disease, J. Alzheimers Dis., 9, 119, 10.3233/JAD-2006-9204 Barone, 2014, Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets, Biochem. Pharmacol., 88, 605, 10.1016/j.bcp.2013.10.030 Bell, 2008, SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells, Nat. Cell Biol., 11, 143, 10.1038/ncb1819 Bentov, 2013, The aging oocyte—can mitochondrial function be improved?, Fertil. Steril., 99, 18, 10.1016/j.fertnstert.2012.11.031 Bezprovzanny, 2013, Presenilins and calcium signaling-systems biology to the rescue, Sci. Signal., 6, pe24 Blurton-Jones, 2014, Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models, Stem Cell Res. Ther., 5, 46, 10.1186/scrt440 Bonda, 2014, Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass, Neurosci. Bull., 30, 243, 10.1007/s12264-013-1424-x Borchelt, 1996, Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo, Neuron, 17, 1005, 10.1016/S0896-6273(00)80230-5 Bough, 2006, Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet, Ann. Neurol., 60, 223, 10.1002/ana.20899 Boyd, 1990, The protective effect of gamma-hydroxybutyrate in regional intestinal ischemia in the hamster, Gastroenterology, 99, 860, 10.1016/0016-5085(90)90982-7 Boyd, 1994, Intestinal microcirculation and leukocyte behavior in ischemia-reperfusion injury, Microvasc. Res., 47, 355, 10.1006/mvre.1994.1028 Braak, 1991, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol., 82, 239, 10.1007/BF00308809 Braak, 1996, Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis, Acta Neuropathol., 92, 197, 10.1007/s004010050508 Braak, 1997, Frequency of stages of Alzheimer-related lesions in different age categories, Neurobiol. Aging, 18, 351, 10.1016/S0197-4580(97)00056-0 Braak, 2011, Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?, Acta Neuropathol., 121, 589, 10.1007/s00401-011-0825-z Braak, 2012, Where, when, and in what form does sporadic Alzheimer’s disease begin?, Curr. Opin. Neurol., 25, 708, 10.1097/WCO.0b013e32835a3432 Braak, 2013, Reply: the early pathological process in sporadic Alzheimer’s disease, Acta Neuropathol., 126, 615, 10.1007/s00401-013-1170-1 Braak, 2015, The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease, Brain, 138, 2814, 10.1093/brain/awv236 Braak, 1994, A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads, Acta Neuropathol., 87, 554, 10.1007/BF00293315 Braak, 2006, Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry, Acta Neuropathol., 112, 389, 10.1007/s00401-006-0127-z Braak, 2006, Vulnerability of cortical neurons to Alzheimer’s and Parkinson’s diseases, J. Alzheimers Dis., 9, S35, 10.3233/JAD-2006-9S305 Braak, 2011, Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years, J. Neuropathol. Exp. Neurol., 70, 960, 10.1097/NEN.0b013e318232a379 Braak, 2013, Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid, Acta Neuropathol., 126, 631, 10.1007/s00401-013-1139-0 Brown, 2011, Review: cerebral microvascular pathology in ageing and neurodegeneration, Neuropathol. Appl. Neurobiol., 37, 56, 10.1111/j.1365-2990.2010.01139.x Bubber, 2005, Mitochondrial abnormalities in Alzheimer brain: mechanistic implications, Ann. Neurol., 57, 695, 10.1002/ana.20474 Buee, 1994, Pathological alterations of the cerebral microvasculature in Alzheimer’s disease and related dementing disorders, Acta Neuropathol., 87, 469, 10.1007/BF00294173 Busciglio, 1995, Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro, Nature, 378, 776, 10.1038/378776a0 Busciglio, 2002, Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down’s syndrome, Neuron, 33, 677, 10.1016/S0896-6273(02)00604-9 Caceda, 2001, Energetic metabolism in mouse cerebral cortex during chronic hypoxia, Neurosci. Lett., 301, 171, 10.1016/S0304-3940(01)01630-5 Carnevale, 2012, Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature, Hypertension, 60, 188, 10.1161/HYPERTENSIONAHA.112.195511 Carvalho, 2016, Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease, J. Neural. Transm., 123, 107, 10.1007/s00702-015-1367-7 Cash, 2003, Microtubule reduction in Alzheimer’s disease and aging is independent of tau filament formation, Am. J. Pathol., 162, 1623, 10.1016/S0002-9440(10)64296-4 Castellani, 2014, The complexities of the pathology-pathogenesis relationship in Alzheimer disease, Biochem. Pharmacol., 88, 671, 10.1016/j.bcp.2014.01.009 Castellani, 2007, Iron: the Redox-active center of oxidative stress in Alzheimer disease, Neurochem. Res., 32, 1640, 10.1007/s11064-007-9360-7 Castellano, 2015, Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer’s disease dementia, J. Alzheimers Dis., 43, 1343, 10.3233/JAD-141074 Cataldo, 1997, Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased beta-amyloidosis, J. Neurosci., 17, 6142, 10.1523/JNEUROSCI.17-16-06142.1997 Cataldo, 2000, Endocytic pathway abnormalities preede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome, Am. J. Pathol., 157, 277, 10.1016/S0002-9440(10)64538-5 Chau, 2012, Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of gamma-secretase, J. Biol. Chem., 287, 17288, 10.1074/jbc.M111.300483 Chen, 2011, Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease, J. Biol. Chem., 286, 5215, 10.1074/jbc.M110.151084 Chen, 2016, Targeting insulin signaling for the treatment of Alzheimer’s disease, Curr. Top. Med. Chem., 16, 485, 10.2174/1568026615666150813142423 Cheng, 2009, Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson’s disease, Brain Res., 1286, 25, 10.1016/j.brainres.2009.06.060 Chetelat, 2012, Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition, Neurology, 78, 477, 10.1212/WNL.0b013e318246d67a Chuang, 2014, Use of diuretics is associated with reduced risk of Alzheimer’s disease: the Cache County Study, Neurobiol. Aging, 35, 2429, 10.1016/j.neurobiolaging.2014.05.002 Chui, 2012, Vascular risk factors and Alzheimer.s disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence –based review, Alzheimers Res. Ther., 4, 1 Coskun, 2010, Systemic mitochondrial dysfunction and the etiology of Alzheimer’s disease and Down syndrome dementia, J. Alzheimers Dis., 20, S293, 10.3233/JAD-2010-100351 Cunnane, 2016, Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease, Ann. N. Y. Acad. Sci., 1367, 12, 10.1111/nyas.12999 Dawes, 1973, The role and regulation of energy reserve polymers in micro-organisms, Adv. Microb. Physiol., 10, 135, 10.1016/S0065-2911(08)60088-0 De Jong, 1999, Cerebral hypoperfusion yields capillary damage in the hippocampal CA1 area that correlates with spatial memory impairment, Neuroscience, 91, 203, 10.1016/S0306-4522(98)00659-9 Doi, 1990, Biosynthesis and characterization of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) in Alcaligenes eutrophus, Int. J. Biol. Macromol., 12, 106, 10.1016/0141-8130(90)90061-E Dries, 2012, Extracting beta-amyloid from Alzheimer’s disease, Proc. Natl. Acad. Sci. U. S. A., 109, 3199, 10.1073/pnas.1121560109 Duyckaerts, 1997, Prevalence, incidence and duration of Braak’s stages in the general population: can we know?, Neurobiol. Aging, 18, 362, 10.1016/S0197-4580(97)00047-X Duyckaerts, 2015, PART is part of Alzheimer disease, Acta Neuropathol., 129, 749, 10.1007/s00401-015-1390-7 Eisele, 2010, Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis, Science, 330, 980, 10.1126/science.1194516 Faraci, 2005, Oxidative stress: the curse that underlies cerebral vascular dysfunction?, Stroke, 36, 186, 10.1161/01.STR.0000153067.27288.8b Faraci, 2011, Protecting against vascular disease in brain, Am. J. Physiol. Heart Circ. Physiol., 300, H1566, 10.1152/ajpheart.01310.2010 Finch, 2015, Commentary: is Alzheimer’s disease uniquely human?, Neurobiol. Aging, 36, 553, 10.1016/j.neurobiolaging.2014.10.025 Fischer, 1990, Altered angioarchitecture in selected areas of brains with Alzheimer’s disease, Acta Neuropathol., 79, 672, 10.1007/BF00294246 Frost, 2010, Prion-like mechanisms in neurodegenerative diseases, Nat. Rev. Neurosci., 11, 155, 10.1038/nrn2786 Funk, 2011, Granulovacuolar degeneration (GVD) bodies of Alzheimer’s disease (AD) resemble late-stage autophagic organelles, Neuropathol. Appl. Neurobiol., 37, 295, 10.1111/j.1365-2990.2010.01135.x Gama Sosa, 2010, Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer’s disease mutations, Am. J. Pathol., 176, 353, 10.2353/ajpath.2010.090482 Garlet, 2013, Systemic oxidative stress in children and teenagers with Down syndrome, Life Sci., 93, 558, 10.1016/j.lfs.2013.08.017 Gatz, 1997, Heritability for Alzheimer’s disease: the study of dementia in Swedish twins, J. Gerontol. Ser. A-Biol. Sci. Med. Sci., 52, M117, 10.1093/gerona/52A.2.M117 Gaziev, 2014, Mitochondrial function and mitochondrial DNA maintenance with advancing age, Biogerontology, 15, 417, 10.1007/s10522-014-9515-2 Ghebremedhin, 1998, High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer’s disease-related neurofibrillary changes, Exp. Neurol., 153, 152, 10.1006/exnr.1998.6860 Ginsburg, 2010, Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression, Biol. Psychiatry, 68, 885, 10.1016/j.biopsych.2010.05.030 Glodzik, 2014, Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly, Neurobiol. Aging, 35, 64, 10.1016/j.neurobiolaging.2013.06.011 Gonzalez-Lima, 2014, Mitochondrial respiration as a target for neuroprotection and cognitive enhancement, Biochem. Pharmacol., 88, 584, 10.1016/j.bcp.2013.11.010 Grammas, 2011, Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases, Expert Rev. Mol. Med., 13, e19, 10.1017/S1462399411001918 Haller, 1990, Effect of gamma-hydroxybutyrate on local and global glucose metabolism in the anesthetized cat brain, J. Cereb. Blood Flow Metab., 10, 493, 10.1038/jcbfm.1990.91 Hardy, 2002, The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Hashim, 2014, Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester, J. Lipid Res., 55, 1818, 10.1194/jlr.R046599 Hasselbalch, 1996, Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia, Am. J. Physiol., 270, E746 Helguera, 2013, Adaptive downregulation of mitochondrial function in Down syndrome, Cell Metab., 17, 132, 10.1016/j.cmet.2012.12.005 Henderson, 2011, Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer’s disease; a randomized, double-blind, placebo-controlled study, BMC Med. Genet., 12, 137, 10.1186/1471-2350-12-137 Henderson, 2009, Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial, Nutr. Metab (Lond.), 6, 31, 10.1186/1743-7075-6-31 Henderson, 2014, Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β, Brain, 137, 53, 10.1093/brain/awt308 Hertz, 2015, Effects of ketone bodies in Alzheimer’s disease in relation to neural hypometabolism, beta-amyloid toxicity, and astrocyte function, J. Neurochem., 134, 7, 10.1111/jnc.13107 Hirai, 2001, Mitochondrial abnormalities in Alzheimer’s disease, J. Neurosci., 21, 3017, 10.1523/JNEUROSCI.21-09-03017.2001 Holmes, 2008, Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 372, 216, 10.1016/S0140-6736(08)61075-2 Honda, 2005, Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron, J. Biol. Chem., 280, 20978, 10.1074/jbc.M500526200 Hoozemans, 2005, The unfolded protein response is activated in Alzheimer’s disease, Acta Neuropathol., 110, 165, 10.1007/s00401-005-1038-0 Hoozemans, 2009, The unfolded protein response is activated in pretangle neurons in Alzheimer’s disease hippocampus, Am. J. Pathol., 174, 1241, 10.2353/ajpath.2009.080814 Ihara, 2012, The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease, Cold Spring Harbor Perspect. Med., 2, 10.1101/cshperspect.a006361 Iqbal, 2014, Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles, Biochem. Pharmacol., 88, 631, 10.1016/j.bcp.2014.01.002 Itsara, 2014, Oxidative stress is not a major contributor to somatic mitochondrial DNA mutations, PLoS Genet., 10, e1003974, 10.1371/journal.pgen.1003974 Jack, 2013, Brain beta-amyloid load approaches a plateau, Neurology, 80, 890, 10.1212/WNL.0b013e3182840bbe Jack, 2014, Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration, Neurology, 82, 1605, 10.1212/WNL.0000000000000386 Jarrett, 2008, The ketogenic diet increases mitochondrial glutathione levels, J. Neurochem., 106, 1044, 10.1111/j.1471-4159.2008.05460.x Jauch-Chara, 2012, Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans, Diabetes, 61, 2261, 10.2337/db12-0025 Jellinger, 2015, PART, a distinct tauopathy, different from classical sporadic Alzheimer disease, Acta Neuropathol., 129, 757, 10.1007/s00401-015-1407-2 Jin, 2014, Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes, Biochim. Biophys. Acta, 1842, 1282, 10.1016/j.bbadis.2013.09.007 Josephs, 2008, Beta-amyloid burden is not associated with rates of brain atrophy, Ann. Neurol., 63, 204, 10.1002/ana.21223 Jovanovic, 1998, Biomarkers of oxidative stress are significantly elevated in Down syndrome, Free Radic. Biol. Med., 25, 1044, 10.1016/S0891-5849(98)00137-3 Julio-Amilpas, 2015, Protection of hypoglycemia-induced neuronal death by β-hydroxybutyrate involves preservation of energy levels and decreased production of reactive oxygen species, J. Cereb. Blood Flow Metab., 35, 851, 10.1038/jcbfm.2015.1 Kashiwaya, 2000, D-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease, Proc. Natl. Acad. Sci. U. S. A., 97, 5440, 10.1073/pnas.97.10.5440 Kashiwaya, 2010, A ketone ester diet increases brain malonyl-CoA and Uncoupling proteins 4 and 5 while decreasing food intake in the normal Wistar Rat, J. Biol. Chem., 285, 25950, 10.1074/jbc.M110.138198 Kashiwaya, 2013, A ketone ester diet exhibits anxiolytic and cognition-sparing properties: and lessens amyloid and tau pathologies in a mouse model of Alzheimer’s disease, Neurobiol. Aging, 34, 1530, 10.1016/j.neurobiolaging.2012.11.023 Keefe, 1995, Mitochondrial deoxyribonucleic acid deletions in oocytes and reproductive aging in women, Fertil. Steril., 64, 577, 10.1016/S0015-0282(16)57796-6 Kelleher, 2013, Evidence of endothelial dysfunction in the development of Alzheimer’s disease: is Alzheimer’s a vascular disorder?, Am. J. Cardiovasc. Dis., 3, 197 Kelley, 2014, Cognitive effects of statin medications, CNS Drugs, 28, 411, 10.1007/s40263-014-0147-5 Kennedy, 2013, Ultra-sensitive sequencing reveals an age-related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage, PLoS Genet., 9, e1003794, 10.1371/journal.pgen.1003794 Klein, 2009, Pharmacological doses of gamma-hydroxybutyrate (GHB) potentiate histone acetylation in the rat brain by histone deacetylase inhibition, Neuropharmacology, 57, 137, 10.1016/j.neuropharm.2009.04.013 Klein, 2015, gamma-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer’s disease, Neurobiol. Aging, 36, 832, 10.1016/j.neurobiolaging.2014.10.003 Knopman, 2014, beta-Amyloidosis and neurodegeneration in Alzheimer disease: who’s on first?, Neurology, 82, 1756, 10.1212/WNL.0000000000000438 Kolin, 1993, Cardioprotective action of sodium gamma-hydroxybutyrate against isoproterenol induced myocardial damage, Int. J. Exp. Pathol., 74, 275 Lagouge, 2013, The role of mitochondrial DNA mutations and free radicals in disease and ageing, J. Intern. Med., 273, 529, 10.1111/joim.12055 Lavenex, 2011, Developmental regulation of gene expression and astrocytic processes may explain selective hippocampal vulnerability, Hippocampus, 21, 142, 10.1002/hipo.20730 Lavyne, 1983, Effect of low dose gamma-butyrolactone therapy on forebrain neuronal ischemia in the unrestrained, awake rat, Neurosurgery, 12, 430, 10.1227/00006123-198304000-00010 Lee, 2005, Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms, Exp. Neurol., 194, 91, 10.1016/j.expneurol.2005.01.026 Leopold, 2003, Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide, Arterioscler. Thromb. Vasc. Biol., 23, 411, 10.1161/01.ATV.0000056744.26901.BA Li, 2007, Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer’s neurodegeneration, Proc. Natl. Acad. Sci. U. S. A., 104, 3591, 10.1073/pnas.0609303104 Liu, 2008, Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease, FEBS Lett., 582, 359, 10.1016/j.febslet.2007.12.035 Liu, 2009, Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease, Brain, 132, 1820, 10.1093/brain/awp099 Liu, 2010, Nanoparticle and iron chelators as a potential novel Alzheimer therapy, Methods Mol. Biol., 610, 123, 10.1007/978-1-60327-029-8_8 Liu, 2012, Trans-synaptic spread of tau pathology in vivo, PLoS One, 7, e31302, 10.1371/journal.pone.0031302 Lonze, 2002, Function and regulation of CREB family transcription factors in the nervous system, Neuron, 35, 605, 10.1016/S0896-6273(02)00828-0 Love, 2016, Cerebrovascular disease in ageing and Alzheimer’s disease, Acta Neuropathol., 131, 645, 10.1007/s00401-015-1522-0 Love, 2016, Cerebral hypoperfusion and the energy deficit in Alzheimer’s disease, Brain Pathol., 26, 607, 10.1111/bpa.12401 MacMillan, 1978, The effects of gamma-hydroxybutyrate and gamma-butyrolactone upon the energy metabolism of the normoxic and hypoxic rat brain, Brain Res., 146, 177, 10.1016/0006-8993(78)90229-9 Mahley, 2012, Apolipoprotein e sets the stage: response to injury triggers neuropathology, Neuron, 76, 871, 10.1016/j.neuron.2012.11.020 Maitre, 2016, A proposed preventive role for gamma-hydroxybutyrate (Xyrem) in Alzheimer’s disease, Alzheimers Res. Ther., 8, 37, 10.1186/s13195-016-0205-y Malini, 2006, Influence of advanced age of maternal grandmothers on Down syndrome, BMC Med. Genet., 7, 4, 10.1186/1471-2350-7-4 Mamelak, 2002, γ-Hydroxybutyrate and oxidative stress, 218 Mamelak, 2007, Alzheimer’ s disease, oxidative stress and gammahydroxybutyrate, Neurobiol. Aging, 28, 1340, 10.1016/j.neurobiolaging.2006.06.008 Mamelak, 2009, Narcolepsy and depression and the neurobiology of gammahydroxybutyrate, Prog. Neurobiol., 89, 193, 10.1016/j.pneurobio.2009.07.004 Mamelak, 2012, Sporadic Alzheimer’s disease: the starving brain, J. Alzheimers Dis., 31, 459, 10.3233/JAD-2012-120370 Mann, 2013, Amyloid or tau: the chicken or the egg?, Acta Neuropathol., 126, 609, 10.1007/s00401-013-1162-1 McCarron, 2001, Hibernation, a state of profound intolerance to profound reduction in organ blood flow and oxygen delivery capacity, 23 McKee, 2009, Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury, J. Neuropathol. Exp. Neurol., 68, 709, 10.1097/NEN.0b013e3181a9d503 McKee, 2015, The neuropathology of chronic traumatic encephalopathy, Brain Pathol., 25, 350, 10.1111/bpa.12248 Mecocci, 2012, Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease, Biochim. Biophys. Acta, 1822, 631, 10.1016/j.bbadis.2011.10.006 Miller, 2008, Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease, Brain Res., 1230, 273, 10.1016/j.brainres.2008.06.124 Miners, 2016, Pathophysiology of hypoperfusion of the precuneus in early Alzheimer’s disease, Brain Pathol., 26, 533, 10.1111/bpa.12331 Miyata, 1996, Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides, Nat. Genet., 14, 55, 10.1038/ng0996-55 Montagne, 2015, Vascular plasticity and cognition during normal aging and dementia, JAMA Neurol., 72, 495, 10.1001/jamaneurol.2014.4636 Montagne, 2015, Blood-brain barrier breakdown in the aging human hippocampus, Neuron, 85, 296, 10.1016/j.neuron.2014.12.032 Montine, 1997, Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer’s disease is associated with inheritance of APOE4, Am. J. Pathol., 150, 437 Moreira, 2006, Brain and brawn: parallels in oxidative strength, Neurology, 66, S97, 10.1212/01.wnl.0000192307.15103.83 Morley, 2014, The role of amyloid-beta in the regulation of memory, Biochem. Pharmacol., 88, 479, 10.1016/j.bcp.2013.12.018 Morrison, 1998, Determinants of neuronal vulnerability in neurodegenerative diseases, Ann. Neurol., 44, S32, 10.1002/ana.410440706 Morrison, 2013, Oligodendroglia: metabolic supporters of axons, Trends Cell Biol., 23, 644, 10.1016/j.tcb.2013.07.007 Mosconi, 2005, Reduced hippocampal metabolism in MCI and AD: automated FDG-Pet image analysis, Neurology, 64, 1860, 10.1212/01.WNL.0000163856.13524.08 Mosconi, 2010, Maternal transmission of Alzheimer’s disease: prodromal metabolic phenotype and the search for genes, Hum. Genomics, 4, 170, 10.1186/1479-7364-4-3-170 Mosconi, 2011, Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer’s disease, J. Alzheimers Dis., 27, 483, 10.3233/JAD-2011-110866 Mukherjee, 2012, Melatonin protects against isoproterenol-induced alterations in cardiac mitochondrial energy-metabolizing enzymes, apoptotic proteins, and assists in complete recovery from myocardial injury in rats, J. Pineal Res., 53, 166, 10.1111/j.1600-079X.2012.00984.x Neely, 1999, The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin, J. Neurochem., 72, 2323, 10.1046/j.1471-4159.1999.0722323.x Nelson, 2012, Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature, J. Neuropathol. Exp. Neurol., 71, 362, 10.1097/NEN.0b013e31825018f7 Newman, 2014, Ketone bodies as signaling metabolites, Trends Endocrinol. Metab., 25, 42, 10.1016/j.tem.2013.09.002 Newport, 2015, A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer’s disease, Alzheimers Dement., 11, 99, 10.1016/j.jalz.2014.01.006 Nikinmaa, 2004, Redox state regulates HIF-!alpha and its DNA binding and phosphorylation in salmonid cells, J. Cell Sci., 117, 3201, 10.1242/jcs.01192 Noh, 2004, A cDNA microarray analysis of gene expression profiles in rat hippocampus following a ketogenic diet, Brain Res. Mol. Brain Res., 129, 80, 10.1016/j.molbrainres.2004.06.020 Nugent, 2014, Brain glucose and acetoacetate metabolism: a comparison of young and older adults, Neurobiol. Aging, 35, 1386, 10.1016/j.neurobiolaging.2013.11.027 Nunomura, 1999, Neuronal RNA oxidation in Alzheimer’s disease and Down’s syndrome, Ann. N. Y. Acad. Sci., 893, 362, 10.1111/j.1749-6632.1999.tb07855.x Nunomura, 2000, Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome, J. Neuropathol. Exp. Neurol., 59, 1011, 10.1093/jnen/59.11.1011 Nunomura, 2001, Oxidative damage is the earliest event in Alzheimer disease, J. Neuropathol. Exp. Neurol., 60, 759, 10.1093/jnen/60.8.759 Nunomura, 2009, RNA oxidation in Alzheimer disease and related neurodegenerative disorders, Acta Neuropathol., 118, 151, 10.1007/s00401-009-0508-1 Nunomura, 2012, The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons, J. Neuropathol. Exp. Neurol., 71, 233, 10.1097/NEN.0b013e318248e614 Ogunshola, 2009, Contribution of hypoxia to Alzheimer’s disease: is HIF-1α a mediator of neurodegeneration?, Cell. Mol. Life Sci., 66, 3555, 10.1007/s00018-009-0141-0 Ottani, 2003, Effect of gamma-hydroxybutyrate in two rat models of focal cerebral damage, Brain Res., 986, 181, 10.1016/S0006-8993(03)03252-9 Owen, 1967, Brain metabolism during fasting, J. Clin. Invest., 46, 1589, 10.1172/JCI105650 Palmer, 2013, Endothelin-converting enzyme-1 activity, endothelin-1-production and fee radical-dependent vasoconstriction in Alzheimer’s disease, J. Alzheimers Dis., 36, 577, 10.3233/JAD-130383 Piccoli, 2013, Chronic pro-oxidative state and mitochondrial dysfunctions are more pronounced in fibroblasts from Down syndrome foeti with congenital heart defects, Hum. Mol. Genet., 22, 1218, 10.1093/hmg/dds529 Pifferi, 2011, Mild experimental ketosis increases brain uptake of 11C-acetoacetate and 18F-fluorodeoxyglucose: a dual-tracer PET imaging study in rats, Nutr. Neurosci., 14, 51, 10.1179/1476830510Y.0000000001 Plant, 2003, The production of amyloid beta peptide is a critical requirement for the viability of central neurons, J. Neurosci., 23, 5531, 10.1523/JNEUROSCI.23-13-05531.2003 Popov, 1992, Hibernation-induced structural changes in synaptic contacts between mossy fibres and hippocampal pyramidal neurons, Neuroscience, 48, 53, 10.1016/0306-4522(92)90337-2 Popov, 1992, Repeated changes of dendritic morphology in the hippocampus of ground squirrels in the course of hibernation, Neuroscience, 48, 45, 10.1016/0306-4522(92)90336-Z Price, 1999, Tangles and plaques in nondemented aging and preclinical Alzheimer’s disease, Ann. Neurol., 45, 358, 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X Puchowicz, 2008, Neuroprotection in diet-induced ketotic rat brain after focal ischemia, J. Cereb. Blood Flow Metab., 28, 1907, 10.1038/jcbfm.2008.79 Raiha, 1997, Alzheimer’s disease in twins, Biomed. Pharmacother., 5, 101, 10.1016/S0753-3322(97)86906-5 Raina, 2003, Apoptotic promoters and inhibitors in Alzheimer’s disease: who wins out?, Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 251, 10.1016/S0278-5846(03)00020-4 Ramassamy, 1999, Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer’s disease is related to the apolipoprotein E genotype, Free Radic. Biol. Med., 27, 544, 10.1016/S0891-5849(99)00102-1 Reed, 1997, Autosomal dominant dementia with widespread neurofibrillary tangles, Ann. Neurol., 42, 564, 10.1002/ana.410420406 Reiman, 2001, Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease, Proc. Natl. Acad. Sci. U. S. A., 98, 3334, 10.1073/pnas.061509598 Reiman, 2004, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia, Proc. Natl. Acad. Sci. U. S. A., 101, 284, 10.1073/pnas.2635903100 Reitz, 2014, Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers, Biochem. Pharmacol., 88, 640, 10.1016/j.bcp.2013.12.024 Ren, 2006, gamma-Hydroxybutyrate induces cyclic AMP-responsive element-binding protein phosphorylation in mouse hippocampus: an involvement of GABA(B) receptors and cAMP-dependent protein kinase activation, Neuroscience, 141, 269, 10.1016/j.neuroscience.2006.03.056 Roiko, 2012, Brain uptake of the drug of abuse gamma-hydroxybutyric acid in rats, Drug Metab. Dispos., 40, 212, 10.1124/dmd.111.041749 Ruitenberg, 2005, Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study, Ann. Neurol., 57, 789, 10.1002/ana.20493 Sadasivan, 2006, Gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) reduce the volume of cerebral infarction in rodent transient middle cerebral artery occlusion, Ann. N. Y. Acad. Sci., 1074, 537, 10.1196/annals.1369.054 Sadowski, 1999, Entorhinal cortex of aged subjects with Down’s syndrome shows severe neuronal loss caused by neurofibrillary pathology, Acta Neuropathol., 97, 156, 10.1007/s004010050968 Sagare, 2011, From the liver to the blood-brain barrier: an interconnected system regulating brain amyloid-beta levels, J. Neurosci. Res., 89, 967, 10.1002/jnr.22670 Sagare, 2013, Neurovascular defects and faulty amyloid-beta vascular clearance in Alzheimer’s disease, J. Alzheimers Dis., 33, S87 Salminen, 2011, AMP-activated protein kinase: a potential player in Alzheimer’s disease, J. Neurochem., 118, 460, 10.1111/j.1471-4159.2011.07331.x Samoilova, 2010, Chronic in vitro ketosis is neuroprotective but not anti-convulsant, J. Neurochem., 113, 826, 10.1111/j.1471-4159.2010.06645.x Sayre, 1997, 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease, J. Neurochem., 68, 2092, 10.1046/j.1471-4159.1997.68052092.x Scheuner, 1996, Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease, Nat. Med., 2, 864, 10.1038/nm0896-864 Schon, 2013, Mitochondria-associated ER membranes in Alzheimer disease, Mol. Cell. Neurosci., 55, 26, 10.1016/j.mcn.2012.07.011 Schon, 2000, Chromosomal non-disjunction in human oocytes: is there a mitochondrial connection?, Hum. Reprod., 15, 160, 10.1093/humrep/15.suppl_2.160 Schupf, 1994, Increased risk of Alzheimer’s disease in mothers of adults with Down’s syndrome, Lancet, 344, 353, 10.1016/S0140-6736(94)91398-6 Schupf, 2001, Specificity of the fivefold increase in AD in mothers of adults with Down syndrome, Neurology, 57, 979, 10.1212/WNL.57.6.979 Sehgal, 2012, Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver, Proc. Natl. Acad. Sci. U. S. A., 109, 3510, 10.1073/pnas.1112209109 Sepulveda-Falla, 2011, Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer’s disease, Brain Pathol., 21, 452, 10.1111/j.1750-3639.2010.00469.x Sepulveda-Falla, 2014, Familial Alzheimer’s disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis, J. Clin. Invest., 124, 1552, 10.1172/JCI66407 Shimazu, 2013, Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor, Science, 339, 211, 10.1126/science.1227166 Sims, 1994, Delayed treatment with 1,3-butanediol reduces loss of CA1 neurons in the hippocampus of rats following brief forebrain ischemia, Brain Res., 662, 216, 10.1016/0006-8993(94)90815-X Slooter, 1998, Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study, Arch. Neurol., 55, 964, 10.1001/archneur.55.7.964 Smith, 2002, Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain, Free Radic. Biol. Med., 33, 1194, 10.1016/S0891-5849(02)01021-3 Snowdon, 1997, Brain infarction and the clinical expression of Alzheimer disease. The Nun Study, JAMA, 277, 813, 10.1001/jama.1997.03540340047031 Soucek, 2003, The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide, Neuron, 39, 43, 10.1016/S0896-6273(03)00367-2 Srikanth, 2011, Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease, Neurobiol. Aging, 32, 763, 10.1016/j.neurobiolaging.2009.04.016 Story, 2005, Biochemical adaptation to extreme environments, 169 Su, 2008, Physiological regulation of tau phosphorylation during hibernation, J. Neurochem., 105, 2098, 10.1111/j.1471-4159.2008.05294.x Su, 2010, Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells, Neurosci. Lett., 468, 267, 10.1016/j.neulet.2009.11.010 Sultana, 2013, Oxidative modification of brain proteins in Alzheimer’s disease: perspective on future studies based on results of redox proteomics studies, J. Alzheimers Dis., 33, S243 Sultana, 2008, Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment, Neurochem. Res., 33, 2540, 10.1007/s11064-008-9593-0 Sutcliffe, 2011, Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer’s disease, J. Neurosci. Res., 89, 808, 10.1002/jnr.22603 Suzuki, 2001, Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats, Jpn. J. Pharmacol., 87, 143, 10.1254/jjp.87.143 Suzuki, 2002, Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia, Jpn. J. Pharmacol., 89, 36, 10.1254/jjp.89.36 Swerdlow, 2014, The Alzheimer’s disease metabolic cascade hypothesis: progress and perspectives, Biochim. Biophys. Acta, 1842, 1219, 10.1016/j.bbadis.2013.09.010 Szczepanowska, 2012, Effect of mtDNA point mutations on cellular bioenergetics, Biochim. Biophys. Acta, 1817, 1740, 10.1016/j.bbabio.2012.02.028 Szpak, 2007, Small cerebral vessel disease in familial amyloid and non-amyloid angiopathies: FAD-PS-1 (P117L) mutation and CADASIL. Immunohistochemical and ultrastructural studies, Folia Neuropathol., 45, 192 Tanzi, 2005, Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective, Cell, 120, 545, 10.1016/j.cell.2005.02.008 Teller, 1996, Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down’s syndrome, Nat. Med., 2, 93, 10.1038/nm0196-93 Terry, 1996, The pathogenesis of Alzheimer’s disease: an alternative to the amyloid hypothesis, J. Neuropathol. Exp. Neurol., 55, 1023, 10.1097/00005072-199655100-00001 Terry, 1998, The cytoskeleton in Alzheimer disease, J. Neural Transm. Suppl., 53, 141, 10.1007/978-3-7091-6467-9_12 Tieu, 2003, D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease, J. Clin. Invest., 112, 892, 10.1172/JCI200318797 Tong, 2016, Targeting Alzheimer’s disease neuro-metabolic dysfunction with a small molecule nuclear receptor agonist (T3D-959) reverses disease pathologies, J. Alzheimers Dis. Parkinsonism, 6, 10.4172/2161-0460.1000238 Van der Auwera, 2005, A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease, Nutr. Metab. (London), 2, 28, 10.1186/1743-7075-2-28 VanItallie, 2015, Biomarkers, ketone bodies, and the prevention of Alzheimer’s disease, Metabolism, 64, S51, 10.1016/j.metabol.2014.10.033 Veech, 2004, The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism, Prostaglandins Leukot. Essent. Fatty Acids, 70, 309, 10.1016/j.plefa.2003.09.007 Verghese, 2011, Apolipoprotein E in Alzheimer’s disease and other neurological disorders, Lancet Neurol., 10, 241, 10.1016/S1474-4422(10)70325-2 Villemagne, 2013, Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study, Lancet Neurol., 12, 357, 10.1016/S1474-4422(13)70044-9 Vingtdeux, 2011, AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies, Acta Neuropathol., 121, 337, 10.1007/s00401-010-0759-x Vogelsberg-Ragaglia, 2001, PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus, Exp. Neurol., 168, 402, 10.1006/exnr.2001.7630 Wang, 2008, Microtubule-associated protein tau in development, degeneration and protection of neurons, Prog. Neurobiol., 85, 148, 10.1016/j.pneurobio.2008.03.002 Wang, 2003, Oxidized neprilysin in aging and Alzheimer’s disease brains, Biochem. Biophys. Res. Commun., 310, 236, 10.1016/j.bbrc.2003.09.003 Wang, 2005, Calorie restriction attenuates β- amyloid neuropathology in mouse model of Alzheimer’s disease, FASEB J., 19, 659, 10.1096/fj.04-3182fje Wang, 2014, Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer’s disease, Neurosci. Bull., 30, 359, 10.1007/s12264-013-1415-y Wang, 2014, Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease, Biochim. Biophys. Acta, 1842, 1240, 10.1016/j.bbadis.2013.10.015 Wei, 2004, Gamma-hydroxybutyrate protects the liver from warm ischemia-reperfusion injury in rat, Hepatobiliary Pancreat. Dis. Int., 3, 245 Wendt, 2014, Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death, Neuroscience, 263, 203, 10.1016/j.neuroscience.2013.12.067 Whitwell, 2008, MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study, Neurology, 71, 743, 10.1212/01.wnl.0000324924.91351.7d Wischik, 2015, Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease, J. Alzheimers Dis., 44, 705, 10.3233/JAD-142874 Wisniewski, 2014, Immunotherapy for Alzheimer’s disease, Biochem. Pharmacol., 88, 499, 10.1016/j.bcp.2013.12.020 Wu, 2005, Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease, Nat. Med., 11, 959, 10.1038/nm1287 Wu, 2013, Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons, J. Biol. Chem., 288, 1856, 10.1074/jbc.M112.394528 Yan, 1996, RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease, Nature, 382, 685, 10.1038/382685a0 Yao, 2011, 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer’s disease, PLoS One, 6, e21788, 10.1371/journal.pone.0021788 Yoshiyama, 2013, Therapeutic strategies for tau mediated neurodegeneration, J. Neurol. Neurosurg. Psychiatry, 84, 784, 10.1136/jnnp-2012-303144 Zana, 2006, Age-dependent oxidative stress-induced DNA damage in Down’s lymphocytes, Biochem. Biophys. Res. Commun., 345, 726, 10.1016/j.bbrc.2006.04.167 Zhang, 2013, 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer’s disease via mitochondria protection mechanism, Biomaterials, 34, 7552, 10.1016/j.biomaterials.2013.06.043 Zhong, 2009, Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure, J. Biol. Chem., 284, 6027, 10.1074/jbc.R800009200 Zhu, 2007, Vascular oxidative stress in Alzheimer disease, J. Neurol. Sci., 257, 240, 10.1016/j.jns.2007.01.039 Zlokovic, 2004, Clearing amyloid through the blood-brain barrier, J. Neurochem., 89, 807, 10.1111/j.1471-4159.2004.02385.x Zlokovic, 2011, Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders, Nat. Rev. Neurosci., 12, 723, 10.1038/nrn3114 Zlokovic, 2013, Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease, JAMA Neurol., 70, 440, 10.1001/jamaneurol.2013.2152